<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Schizophrenia.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:31:07 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="1259003">
<meta name="Category" content="Concern">
<meta name="Article" content="Schizophrenia">
<title>Esquizofrenia-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">Esquizofrenia</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="Schizophrenia.htm">Volver al
art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Hall K. Allergy of the nervous system: a review. <em>Ann Allergy</em>
1976;36:49&#8211;64 [review].</li>

<li class="Ref">Kety SS. Editorial: Dietary factors and schizophrenia. <em>Ann Intern Med</em>
1976;84:745 [editorial].</li>

<li class="Ref">Ross-Smith P, Jenner FA. Diet (gluten) and schizophrenia. <em>J Hum Nutr</em>
1980;34:107&#8211;12 [review].</li>

<li class="Ref">Dohan FC. Genetic hypothesis of idiopathic schizophrenia: its exorphin
connection. <em>Schizophr Bull</em> 1988;14:489&#8211;94.</li>

<li class="Ref">Reichelt KL, Landmark J. Specific IgA antibody increases in schizophrenia.
<em>Biol Psychiatry</em> 1995;37:410&#8211;3.</li>

<li class="Ref">Dohan FC, Grasberger JC. Relapsed schizophrenics: earlier discharge from the
hospital after cereal-free, milk-free diet. <em>Am J Psychiatry</em>
1973;130:685&#8211;8.</li>

<li class="Ref">Singh MM, Kay SR. Wheat gluten as a pathogenic factor in schizophrenia. <em>
Science</em> 1976;191:401&#8211;2.</li>

<li class="Ref">Vlissides DN, Venulet A, Jenner FA. A double-blind gluten-free/gluten-load
controlled trial in a secure ward population. <em>Br J Psychiatry</em>
1986;148:447&#8211;52.</li>

<li class="Ref">Davis C. Dietary pathogenesis of schizophrenia: an investigation into the
effects of gluten. <em>Nurs Times</em> 1978;74:2020&#8211;1.</li>

<li class="Ref">Potkin SG, Weinberger D, Kleinman J, et al. Wheat gluten challenge in
schizophrenic patients. <em>Am J Psychiatry</em> 1981;138:1208&#8211;11.</li>

<li class="Ref">Storms LH, Clopton JM, Wright C. Effects of gluten on schizophrenics<em>. Arch
Gen Psychiatry</em> 1982;39:323&#8211;7.</li>

<li class="Ref">Taylor CB, Sallis JF, Needle R. The relation of physical activity and exercise
to mental health. <em>Public Health Rep</em> 1985;100:195&#8211;202 [review].</li>

<li class="Ref">Adams L. How exercise can help people with mental health problems. <em>Nurs
Times</em> 1995;91:37&#8211;9.</li>

<li class="Ref">Belcher TL. Behavioral reduction of overt hallucinatory behavior in a chronic
schizophrenic. <em>J Behav Ther Exp Psychiatry</em> 1988;19:69&#8211;71.</li>

<li class="Ref">Conroy RW, Smith K, Felthous AR. The value of exercise on a psychiatric
hospital unit<em>. Hosp Community Psychiatry</em> 1982;33:641&#8211;5.</li>

<li class="Ref">Herran A, Garcia-Unzueta MT, Amado JA, et al. Folate levels in psychiatric
outpatients. <em>Psychiatry Clin Neurosci</em> 1999;53:531&#8211;3.</li>

<li class="Ref">Carney MW, Sheffield BF. Associations of subnormal serum folate and vitamin
B12 values and effects of replacement therapy. <em>J Nerv Ment Dis</em>
1970;150:404&#8211;12.</li>

<li class="Ref">Procter A. Enhancement of recovery from psychiatric illness by methylfolate.
<em>Br J Psychiatry</em> 1991;159:271&#8211;2.</li>

<li class="Ref">Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and
&#8220;schizophrenia.&#8221; A defect in methylation due to deficient
5,10-methylenetetrahydrofolate reductase activity. <em>N Engl J Med</em>
1975;292:491&#8211;6.</li>

<li class="Ref">Folate-responsive homocystinuria and &#8220;schizophrenia.&#8221;<em>Nutr
Rev</em> 1982;40:242&#8211;5.</li>

<li class="Ref">Folate-responsive homocystinuria and &#8220;schizophrenia.&#8221;<em>Nutr
Rev</em> 1982;40:242&#8211;5.</li>

<li class="Ref">Waziri R. Glycine therapy of schizophrenia: Some caveats. <em>Biol
Psychiatry</em> 1996;39:155&#8211;6.</li>

<li class="Ref">Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in
the treatment of enduring negative symptoms of schizophrenia. <em>Arch Gen Psychiatry</em>
1999;56:29&#8211;36.</li>

<li class="Ref">Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine
added to clozapine in schizophrenia. <em>Am J Psychiatry</em> 2000;157:826&#8211;8.</li>

<li class="Ref">Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive
high-dose glycine in treatment-resistant schizophrenia. <em>Am J Psychiatry</em>
1999;156:145&#8211;7.</li>

<li class="Ref">Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled,
crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. <em>Br J
Psychiatry</em> 1996;169:610&#8211;7.</li>

<li class="Ref">Javitt DC, Zylberman I, Zukin SR, et al. Amelioration of negative symptoms in
schizophrenia by glycine. <em>Am J Psychiatry</em> 1994;151:1234&#8211;6.</li>

<li class="Ref">Semba J. [Glycine therapy of schizophrenia; its rationale and a review of
clinical trials]. <em>Nihon Shinkei Seishin Yakurigaku Zasshi</em> 1998;18:71&#8211;80
[review] [in Japanese].</li>

<li class="Ref">Rosse RB, Theut SK, Banay-Schwartz M, et al. Glycine adjuvant therapy to
conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. <em>Clin
Neuropharmacol</em> 1989;12:416&#8211;24.</li>

<li class="Ref">Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and
megavitamin therapy. <em>Psychosomatics</em> 1970;11:517&#8211;21 [review].</li>

<li class="Ref">Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and
megavitamin therapy. <em>Psychosomatics</em> 1970;11:517&#8211;21 [review].</li>

<li class="Ref">Autry JH. Workshop on orthomolecular treatment of schizophrenia: a report.
<em>Schizophr Bull</em> 1975:94&#8211;103.</li>

<li class="Ref">Petrie WM, Ban TA. Vitamins in psychiatry. Do they have a role? <em>Drugs</em>
1985;30:58&#8211;65 [review].</li>

<li class="Ref">Hoffer A. Megavitamin B-3 therapy for schizophrenia. <em>Can Psychiatr Assoc
J</em> 1971;16:499&#8211;504.</li>

<li class="Ref">Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of
schizophrenia. <em>Arch Gen Psychiatry</em> 1973;28:308&#8211;15.</li>

<li class="Ref">Newbold HL, Mosher LR. Niacin and the schizophrenic patient. <em>Am J
Psychiatry</em> 1970;127:535&#8211;6.</li>

<li class="Ref">Petrie WM, Ban TA, Ananth JV. The use of nicotinic acid and pyridoxine in the
treatment of schizophrenia<em>. Int</em>&nbsp;<em>Pharmacopsychiatry</em>
1981;16:245&#8211;50.</li>

<li class="Ref">Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of
nicotinic acid by pyridoxine in chronic schizophrenics. <em>Can Psychiatr Assoc J</em>
1973;18:377&#8211;83.</li>

<li class="Ref">Vaughan K, McConaghy N. Megavitamin and dietary treatment in schizophrenia: a
randomised, controlled trial. <em>Aust N Z J Psychiatry</em> 1999;33:84&#8211;8.</li>

<li class="Ref">Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and
psychosis in a schizophrenic patient. <em>Int J Neurosci</em> 1990;52:225&#8211;32.</li>

<li class="Ref">Yamauchi M. Effects of L-dopa and vitamin B6 on electroencephalograms of
schizophrenic patients: a preliminary report. <em>Folia Psychiatr Neurol Jpn</em>
1976;30:121&#8211;51.</li>

<li class="Ref">Bucci L. Pyridoxine and schizophrenia. <em>Br J Psychiatry</em> 1973;122:240
[letter].</li>

<li class="Ref">Sandyk R, Kanofsky JD. Vitamin C in the treatment of schizophrenia. <em>Int J
Neurosci</em> 1993;68:67&#8211;71.</li>

<li class="Ref">Kanofsky JD, Sandyk R. Antioxidants in the treatment of schizophrenia. <em>Int
J Neurosci</em> 1992;62:97&#8211;100 [letter].</li>

<li class="Ref">Kanofsky JD, Sandyk R. Antioxidants in the treatment of schizophrenia. <em>Int
J Neurosci</em> 1992;62:97&#8211;100 [letter].</li>

<li class="Ref">Beauclair L, Vinogradov S, Riney SJ, et al. An adjunctive role for ascorbic
acid in the treatment of schizophrenia? <em>J Clin Psychopharmacol</em> 1987;7:282&#8211;3
[letter].</li>

<li class="Ref">Pitt B, Pollitt N. Ascorbic acid and chronic schizophrenia. <em>Br J
Psychiatry</em> 1971;118:227&#8211;8.</li>

<li class="Ref">Grant FW, Cowen MA, Ozerengin MF, Bigelow N. Nutritional requirements in
mental illness. I. Ascorbic acid retention in schizophrenia. A reexamination. <em>Biol
Psychiatry</em> 1973;5:289&#8211;94.</li>

<li class="Ref">Pitt B. Vitamin C and schizophrenia. <em>Lancet</em> 1974;2:1153&#8211;4
[letter].</li>

<li class="Ref">Suboticanec K, Folnegovic-Smalc V, Turcin R, et al. Plasma levels and urinary
vitamin C excretion in schizophrenic patients. <em>Hum Nutr Clin Nutr</em>
1986;40:421&#8211;8.</li>

<li class="Ref">Suboticanec K, Folnegovic-Smalc V, Korbar M, et al. Vitamin C status in
chronic schizophrenia. <em>Biol Psychiatry</em> 1990;28:959&#8211;66.</li>

<li class="Ref">Horrobin DF. The relationship between schizophrenia and essential fatty acid
and eicosanoid metabolism. <em>Prostaglandins Leukot Essent Fatty Acids</em>
1992;46:71&#8211;7 [review].</li>

<li class="Ref">Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed
throughout the body. <em>Prostaglandins Leukot Essent Fatty Acids</em> 1996;55:3&#8211;7
[review].</li>

<li class="Ref">Warner R, Laugharne J, Peet M, et al. Retinal function as a marker for cell
membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. <em>Biol
Psychiatry</em> 1999;45:1138&#8211;42.</li>

<li class="Ref">Mahadik SP, Mukherjee S, Horrobin DF, et al. Plasma membrane phospholipid
fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison
with bipolar patients and normal subjects. <em>Psychiatry Res</em> 1996;63:133&#8211;42.</li>

<li class="Ref">Vaddadi KS, Gilleard CJ, Soosai E, et al. Schizophrenia, tardive dyskinesia
and essential fatty acids. <em>Schizophr Res</em> 1996;20:287&#8211;94.</li>

<li class="Ref">Peet M, Laugharne J, Rangarajan N, et al. Depleted red cell membrane essential
fatty acids in drug-treated schizophrenic patients. <em>J Psychiatr Res</em>
1995;29:227&#8211;32.</li>

<li class="Ref">Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid
deficiency syndrome: substrate pellagra. <em>Biol Psychiatry</em> 1981;16:837&#8211;50.</li>

<li class="Ref">Puri BK, Richardson AJ, Horrobin DF, et al. Eicosapentaenoic acid treatment in
schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced
neuronal membrane phospholipid turnover and structural brain changes. <em>Int J Clin
Pract</em> 2000;54:57&#8211;63.</li>

<li class="Ref">Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency
in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of
dietary supplementation. <em>Prostaglandins Leukot Essent Fatty Acids</em>
1996;55:71&#8211;5.</li>

<li class="Ref">Laugharne JD, Mellor JE, Peet M. Fatty acids and schizophrenia. <em>
Lipids</em> 1996;31 Suppl:S163&#8211;5.</li>

<li class="Ref">Laugharne JD, Mellor JE, Peet M. Fatty acids and schizophrenia. <em>
Lipids</em> 1996;31 Suppl:S163&#8211;5.</li>

<li class="Ref">Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of
omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and
cognitive impairment in schizophrenia. <em>Am J Psychiatry</em> 2001;158:2071&#8211;4.</li>

<li class="Ref">Vaddadi KS, Courtney P, Gilleard CJ, et al. A double-blind trial of essential
fatty acid supplementation in patients with tardive dyskinesia. <em>Psychiatry Res</em>
1989;27:313&#8211;23.</li>

<li class="Ref">Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in
schizophrenic patients. <em>Hum Psychopharmacol</em> 1996;11:39&#8211;46.</li>

<li class="Ref">Shah S, Ramchand CN, Peet M. Eicosapentaenoic acid (EPA) as an adjunct to
neuroleptic therapy in the treatment of schizophrenia. Presented at the 9th Schizophrenia
Winter Workshop, Davos, Switzerland, February 7&#8211;13, 1998.</li>

<li class="Ref">Mellor JE, Peet M. Double-blind, placebo-controlled, trial of omega-3 fatty
acids as an adjunct to the treatment of schizophrenia. Presented at the 9th Schizophrenia
Winter Workshop, Davos, Switzerland, February 7&#8211;13, 1998.</li>

<li class="Ref">Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane
abnormalities, and the diagnosis and treatment of schizophrenia. <em>Biol Psychiatry</em>
2000;47:8&#8211;21 [review].</li>

<li class="Ref">Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of
patients with chronic schizophrenia. <em>J Clin Psychiatry</em> 2000;61:373&#8211;7.</li>

<li class="Ref">Manowitz P, Gilmour DG, Racevskis J. Low plasma tryptophan levels in recently
hospitalized schizophrenics. <em>Biol Psychiatry</em> 1973;6:109&#8211;18.</li>

<li class="Ref">Payne IR, Walsh EM, Whittenburg EJ. Relationship of dietary tryptophan and
niacin to tryptophan metabolism in schizophrenics and nonschizophrenics. <em>Am J Clin
Nutr</em> 1974;27:565&#8211;71.</li>

<li class="Ref">Gilka L. Schizophrenia, a disorder of tryptophan metabolism. <em>Acta
Psychiatr Scand Suppl</em> 1975;258:1&#8211;83.</li>

<li class="Ref">Bowers MB Jr. Cerebrospinal fluid 5-hydroxyindoles and behavior after
L-tryptophan and pyridoxine administration to psychiatric patients. <em>Neuropharmacology</em>
1970;9:599&#8211;604.</li>

<li class="Ref">Ko SM, Liu TC. Psychiatric syndromes in pernicious anaemia&#8212;a case
report. <em>Singapore Med J</em> 1992;33:92&#8211;4.</li>

<li class="Ref">Ko SM, Liu TC. Psychiatric syndromes in pernicious anaemia&#8212;a case
report. <em>Singapore Med J</em> 1992;33:92&#8211;4.</li>

<li class="Ref">Majumdar SK, Kakad PP. Serum vitamin B12 status in chronic schizophrenic
patients. <em>J Hum Nutr</em> 1981;35:3 [letter].</li>

<li class="Ref">Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the
treatment of schizophrenia. <em>Biol Psychiatry</em> 1998;44:1081&#8211;9.</li>

<li class="Ref">Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial
of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with
schizophrenia. <em>J Clin Psychiatry</em> 2001;62:878&#8211;83.</li>

<li class="Ref">Hoffman RE, Boutros NN, Hu S, et al. Transcranial magnetic stimulation and
auditory hallucinations in schizophrenia. <em>Lancet</em> 2000;355:1073&#8211;5.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Schizophrenia.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:31:07 GMT -->
</html>

